Ratings Moves: MGM,...
Health Care: Drugs
MannKind Corporation (MNKD: NASDAQ)
$6.85 0.62 | 9.95%
05/23/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 35.00K | 50.00K | 93.00K | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 35.00K | 50.00K | 93.00K | 0.00 |
| Selling, General, and Administrative Expenses | 45.47M | 40.63M | 40.31M | 53.45M |
| Research & Development | 101.52M | 99.96M | 112.28M | 156.33M |
| Operating Income before D & A (EBITDA) | -146.96M | -140.54M | -152.50M | -209.78M |
| Depreciation & Amortization | 14.40M | 15.91M | 17.32M | 18.72M |
| Interest Income | 7.00K | 18.00K | 40.00K | 70.00K |
| Other Income - Net | -1.19M | 1.54M | -725.00K | 51.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -162.55M | -154.89M | -170.51M | -228.38M |
| Interest Expense | 21.63M | 21.82M | 17.38M | 10.45M |
| Pre-Tax Income | -184.18M | -176.72M | -187.88M | -238.83M |
| Income Taxes | -408.00K | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -169.37M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -169.37M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -169.37M | -160.80M | -170.56M | -220.10M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-169.37M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -169.37M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.94 | -1.32 | -1.50 | -2.07 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.94 | -1.32 | -1.50 | -2.07 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.94 | -1.32 | -1.50 | -2.07 |
| Basic Normalized Net Income/Share | -0.94 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.94 | -1.32 | -1.50 | -2.07 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.94 | -1.32 | -1.50 | -2.07 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.94 | -1.32 | -1.50 | -2.07 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.94 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with MNKD
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- Userbiomed
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserHoldings
- Contributor10 Most Shorted Stocks in B...
Latest MNKD Headlines from TheStreet
- MannKind's Mysterious Lung-Safety Study Is Open But Shhh...Don't Talk About It 04.17.13 | 09:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- 3 Highly Shorted Stocks Under $5 Bought Up By Hedge Funds 04.09.13 | 01:04 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- These 3 Insider Favorites Are Trading Significantly Below Target Price 01.14.13 | 12:01 pm
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
Press Releases for MNKD
- MannKind Corporation To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 05:02 pm
- MannKind Corporation Reports 2012 Fourth Quarter And Full Year Financial Results - Business Wire 02.11.13 | 04:02 pm
- MannKind Corporation To Hold 2012 Fourth Quarter And Full Year Financial Results Conference Call On February 11, 2013 - Business Wire 02.04.13 | 05:02 pm
- MannKind Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 05:01 pm
- MannKind Corporation To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 05:11 pm
- Faruqi & Faruqi, LLP Launches An Investigation Against Mannkind Corp. (MNKD) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors - Business Wire 11.19.12 | 07:11 pm
- Colby And MannKind Sign License And Joint Development Agreement To Develop And Commercialize Cancer Immunotherapy Products - Business Wire 11.13.12 | 08:11 am
- MannKind Corporation Reports 2012 Third Quarter Financial Results - Business Wire 11.01.12 | 04:11 pm
- MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call To November 1, 2012 Due To Hurricane Sandy - Business Wire 10.29.12 | 02:10 pm
- MannKind Corporation To Hold 2012 Third Quarter Financial Results Conference Call On October 29, 2012 - Business Wire 10.22.12 | 06:10 pm
Partner Headlines for MNKD
- Market Wrap for Wednesday, May 22: Stocks Pullback As Bernanke Says Bond Buying Could Slow - Benzinga 05.22.13 | 04:05 pm
- Mid-Afternoon Market Update: MannKind Posts Huge Rally as Markets Plummet - Benzinga 05.22.13 | 04:05 pm
- U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying - Benzinga 05.18.13 | 03:05 pm
- Why MannKind's Afrezza Will Succeed Where Pfizer Failed - Seeking Alpha 05.18.13 | 04:05 am
- Mid-Afternoon Market Update: Markets Remain Down, Bankrate Rallies - Benzinga 04.12.13 | 03:04 pm
- Long MannKind's Afrezza: Shares Versus A Bull Call Spread - Seeking Alpha 12.01.12 | 07:12 am
- MannKind to Raise Funds - Analyst Blog - Zacks 10.18.12 | 07:10 pm
- MannKind Announces Pricing of Public Offering of Common Stock and Warrants - Benzinga 10.18.12 | 09:10 am
- MNKD Enrolls Patients for Afrezza - Analyst Blog - Zacks 10.08.12 | 06:10 pm
- Company News for September 05, 2012 - Corporate Summary - NASDAQ 09.05.12 | 02:09 pm
